

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HIGHLY SPECIALISED TECHNOLOGY EVALUATION PROGRAMME

Equality impact assessment – Scoping

HST: Arimoclomol for treating Niemann-Pick disease Type C

The impact on equality has been assessed during this evaluation according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was noted during the scoping phase that the clinic trial included people up to the age of 18 years old. Older adults were not included.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The NICE appraisal committee can only make recommendations on the population included within the marketing authorisation for arimoclomol. The committee will consider any issues around age if the evidence permits in its decision making.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Jasdeep Hayre

Date: 28 October 2021